Our team consists of professionals who have trained and operated across the globe and strongly believe in the inter-connectivity and sharing of knowledge and expertise
Sanjay K. Sehgal
Founder Managing Partner & CEO
Sanjay brings over 22 years of global private equity experience, having led or co-led investments worth nearly $350 million of equity.
He is the Chairman of Seraxis, a stem cell research company focused on treating diabetes, operating out of the US and Singapore.
He is a Board member of LiPlasome Pharma ApS, Denmark - an oncology drug delivery company; and Braidlock Limited, a UK medtech company.
He is a Member of The President's Leadership Council at the Hepatitis B Foundation/Baruch S. Blumberg Institute/Pennsylvania Biotechnology Center, in Doylestown, PA.
He is also Senior Advisor to Visterra, Inc, a biotech spinout from MIT, with operations in Singapore. He was recently a Board Member and Chairman of the Audit Committee of an
Australian-listed company, ITL Limited.
Sanjay was a Partner at Schroder Capital Partners (Asia), based out of Singapore and Hong Kong where he helped pioneer the entry of the Schroder private equity Funds' into the Healthcare and Life Sciences domain and geographically into India. Sanjay was an active Board member of private and listed companies in which the Schroder Funds' invested. He was a member of the Investment Committee, for the Schroder Funds' which had $725 million under management and was keenly involved in the negotiated deals in India, USA, Latin America, China, Australasia and southeast Asia.
Prior to joining Schroder Capital Partners, Sanjay worked at LEK Consulting in London and Boston. Previously, he was a Member of Technical Staff at GTE Laboratories (now Verizon) in USA.
Sanjay has a MBA in Finance and Management, with distinction, from The Wharton School, Philadelphia, PA; an MSc in Telecommunications from Columbia University, NY; and a Bachelors degree in Technology (Elec. Engg.), from the Indian Institute of Technology (IIT Bombay).
Sanjay was elected as Hon. Secretary, Singapore Venture Capital & Private Equity Association for 2005 and as Hon. Treasurer in 2004.
He has spoken at numerous healthcare and private equity conferences around the globe.
Duncan Moore formally joined East West Capital Partners in May 2008 having served informally as an advisor since early 2007.
He is the Chairman of Lamellar Biomedical, a Scottish company focused on upper respiratory diseases and also Chairman of Oncology Ventures, a Swedish company which seeks to bring cancer drugs to the market. He is also on the Board of Braidlock Limited, a UK medtech company
Duncan was a top ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm’s global healthcare equity research team. He was
the lead analyst on the European pharmaceutical industry stocks and led the equity research part of the initial public offerings of numerous companies including Wellcome PLC, Sulzer Medica, Biora,
deCODE Genetics, Almirall, Grifols and, Grupo Rovi.
As part of his responsibilities at Morgan Stanley Duncan ran an ideas model portfolio in global healthcare. This involved visiting Asia and India in particular, every year for the last 5 years. It was during these visits that he became aware of the enormity of the expansion capital investment opportunity in the region.
Whilst at the University of Cambridge he co-founded a medical diagnostics company called Ultra Clone with two colleagues which led to the beginnings of a 20 year career in healthcare capital markets analysis. In 1986 he was involved in setting up the Bank Invest biotechnology funds and was on the scientific advisory board.
Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology. He has an M.Phil and Ph.D. from the University of Cambridge where he was also a post doctoral research fellow.
Hans has over 25 years experience in the Medical device industry (manufacturing, sales and distribution, investing, M&A). He has spent the last 18 years in Asia and has a wide network in India, Greater China, and southeast Asia. He has held various advisory roles and board seats in medical device companies in Asia and Europe and has been instrumental in bringing European companies to Asia and vice-versa.
Hans has initiated major development and production projects in India and China and is an expert in medical devices and technology in these countries and across the region.
Prior to East West Capital, Hans Brenner spent over 14 years with B. Braun Melsungen, AG, a privately held German company and one of the largest medical devices
companies in Europe. He was keenly involved in several acquisitions and joint venture transactions worth over US$310 million in Europe and Asia. He was a key executive responsible for valuation,
negotiations and post-merger integration in most of these transactions.
Hans was also President of B. Braun's Asia Pacific operations for 7 years based in Penang, Malaysia, responsible for a €400 million business with 6500 employees. His team building and leadership skills enabled the company to clock a double-digit growth rate annually.
With a Masters degree in Economical Science, from the University of Stuttgart, Hans started his career with Price Waterhouse Coopers and did considerable amount of research, consultancy, and M&A work, prior to joining Aesculap and merging that company with B.Braun.
Ram has over 30 years experience in operations, manufacturing, strategy and business development with pharmaceutical companies worldwide.
His last assignment of 12 years was with Strides Arcolab Limited, a US$280 million market cap Indian generic pharmaceutical, contract manufacturing and research company based in Bangalore. As Executive Director he focused on manufacturing, growth and strategy of the company. Strides grew 300-fold during his 12 year tenure.
Most recently, over the last 5 years, Ram was CEO of Strides Inc, the US subsidiary of Strides Arcolab. He was fully involved in the negotiations and acquisition of this subsidiary. Ram provided the leadership and created the team that enabled turning this into a viable entity. He ensured securing US FDA approval for the plant and raised additional funding for expansion and growth.
Ram started his career in the pharmaceutical division of ICI in India and spent five years there with progressively growing responsibilities. He was an entrepreneur at age 26 and built a pharmaceutical plant in Goa, India on a green field site and sold it after 7 years. Thereafter, Ram was keenly involved with a few other pharmaceutical companies in Germany, India and Hong Kong.
Ram has a Bachelors in Physics and a Masters in Economics.